Printer Friendly

Octapharma Present New Data on the Benefits of Nuwiq In Patients with Haemophilia A.

M2 PHARMA-July 9, 2019-Octapharma Present New Data on the Benefits of Nuwiq In Patients with Haemophilia A

(C)2019 M2 COMMUNICATIONS

- Switzerland-based Octapharma presented new data on the benefits of Nuwiq in patients with haemophilia A during a scientific symposium at the 27th International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia, the company said.

The symposium, entitled 'Conveniently Protecting What Matters: Nuwiq(Simoctocog Alfa) in PUPs and Personalised Prophylaxis', focussed on addressing some of the most important clinical needs of people with haemophilia A, and included final data from the NuProtect Study in previously untreated patients, which were presented for the first time.

The symposium was chaired by Ellis J. Neufeld (St. Jude Children's Research Hospital, Memphis, USA).

No two people with haemophilia A are the same, and therapy should therefore reflect the characteristics and needs of each individual. Robert Klamroth (Vivantes Klinikum, Berlin, Germany) presented data on the use of pharmacokinetic information to personalise prophylaxis with Nuwiq.

In the NuPreviq study, an individualised dosing approach enabled over half of patients to reduce dosing with Nuwiq to twice-weekly or less, whilst providing effective bleed protection, with 83% of people free from spontaneous bleeds during the six months of personalised prophylaxis.

There were no FVIII inhibitors or treatment-related serious or severe adverse events.

Inhibitor development remains a serious treatment complication of haemophilia A, particularly in PUPs, with up to 35% of PUPs developing inhibitors to FVIII.

Ri Liesner (Great Ormond Street Hospital, London, UK) presented for the first time the final data from the NuProtect study, which investigated the development of inhibitors in 108 PUPs treated with Nuwiq.

The cumulative incidence of high-titre inhibitors was only 17.6%, and no patients with non-null F8 gene mutations developed inhibitors. Nuwiqwas well tolerated.

In people with haemophilia A who develop inhibitors, immune tolerance induction is the only approach clinically proven to remove inhibitors and allow people to resume effective FVIII prophylaxis therapy.

Georgina Hall (University of Oxford and John Radcliffe Hospital, Oxford, UK) shared real-world experience of using Nuwiq for ITI, reporting inhibitor elimination in 8 of 10 patients treated so far.

As new treatments become available for people with haemophilia A and inhibitors there is growing interest in the combination of ITI with other products.

Carmen Escuriola Ettingshausen (Haemophilia Centre Rhein Main, Morfelden-Frankfurt, Germany) introduced the investigator-initiated MOTIVATE study, which will investigate the efficacy and safety of "standard of care" ITI vs novel approaches combining FVIII with emicizumab, or emicizumab prophylaxis alone, in people with inhibitors.

Nuwiq is a 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor.

Nuwiq treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children.

Nuwiq is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq are planned.

Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity.

FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage.

This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication.

The cumulative risk of FVIII inhibitor development is reported to be up to 39%.

Octapharma has seven R and D sites and six manufacturing facilities in Austria, France, Germany, Mexico and Sweden.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:8AUST
Date:Jul 9, 2019
Words:659
Previous Article:Takeda Release New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalised Prophylaxis with Adynovate in Severe...
Next Article:Ipsen and Servier Release Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan as an Investigational First-line Treatment for Metastatic...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters